Stock Screener App

無料 - Play StoreApp Store

インストールインストール

Dow:

Nasdaq:

S&P 500:

DXCM

$82.292.95%2.36

アフターアワーズ： 83.50+1.21 +1.47%

Dexcom Inc (DXCM)

Date: O: H: L: C: Vol:

Dexcom Inc (DXCM) 最新ニュース

DexCom Stock Up on Q3 Earnings & Revenue Beat, Margins Rise - Zacks Investment Research

DexCom (DXCM) to Launch Dexcom G7 15 Day CGM System in Canada Ne - GuruFocus

Dexcom launches 15-day glucose monitor in Canada next month By Investing.com - Investing.com India

Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch in Canada in November - DexCom, Inc. - Investor Relations

Dexcom G7 15 Day glucose monitor to launch in Canada in November - StreetInsider

What to expect from DexCom’s (DXCM) Q3 earnings - Yahoo Finance

Here’s How Much You Would Have Made Owning DexCom Stock In The Last 15 Years - Benzinga

Our Dexcom Pick Had a Minor Setback. It’s Still a Diabetes Winner. - Barron's

Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PR Newswire

Is DexCom (DXCM) Cheap After CONNECT Trial Results Backed G7 Adoption? - Simply Wall Street

DexCom Gears Up to Report Q3 Results: How to Play the Stock? - Zacks Investment Research

DexCom Gears Up to Report Q3 Results: How to Play the Stock? - Zacks Investment Research

DexCom Gears Up to Report Q3 Results: How to Play the Stock? - TradingView

Leerink Partners Adjusts Price Target on DexCom to $87 From $94 - marketscreener.com

Dexcom Inc Lobbying Profile, 2020 - OpenSecrets

Form 144 DEXCOM For: 26 October By Investing.com - Investing.com Nigeria

DexCom, Inc. (DXCM) Options Chain - Yahoo Finance - Yahoo! Finance Canada

DexCom, Inc. Estimates – NASDAQ:DXCM - TradingView

Why Is DexCom (DXCM) In Focus After Its G7 Trial Reached NEJM? - Yahoo Finance

DexCom Inc (DXCM) Shares Fall 6.4% -- What GF Score of 95 Tells Investors - GuruFocus

Precision Trading with Dexcom Inc. (DXCM) Risk Zones - Stock Traders Daily

DexCom Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

DexCom (DXCM) Shares Fall 6.5% Amid Broader Market Gains on Octo - GuruFocus

S&P 500 Top Movers on Oct. 21, 2026: Supermicro Leads Gainers, Dexcom Leads Losers - ChartMill

Global Digital Health and Remote Patient Monitoring Strategic Market Report, 2026-2031 | 20.2% CAGR to $80.8 Billion as Connected Care and Wearables Scale - GlobeNewswire Inc.

DexCom Inc. Company & People | DXCM.USD - Barron's

DXCM.USD | DexCom Inc. Stock Overview (Switzerland: SWX) - Barron's

DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study - Zacks Investment Research

DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study - Yahoo! Finance Canada

Form 4 DexCom Inc: Michael Jon Brown (EVP Chief Legal Compliance Off) For: 15 October By Investing.com - Investing.com South Africa

Dexcom EVP Michael Brown sells $145,316 in company stock - Investing.com

Dexcom class action lawsuits claim ShinyHunters stole health data - Top Class Actions

DexCom: The 15-Day Sensor Lowered The Cost Curve Before The Type 2 Wave Arrives - Seeking Alpha

DexCom Inc. stock underperforms Friday when compared to competitors - MarketWatch

DexCom Inc. stock underperforms Friday when compared to competitors - MarketWatch

Dexcom faces a class action over an alleged data breach that ShinyHunters claimed responsibility for. - Claim Depot

Vaso Stock Surges 149% in a Year: What's Behind the Rally? - TradingView

Vaso Stock Surges 149% in a Year: What's Behind the Rally? - Zacks Investment Research

A Look at DexCom Inc (DXCM) After 5.1% Gain -- GF Value $103.59 vs Price $87.71 - GuruFocus

DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch

DexCom gains as NEJM publication boosts Medicare coverage hopes - TradingView

Landmark Dexcom CONNECT Study Published in The New England Journ - GuruFocus

Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin - Dexcom

DexCom Inc. stock underperforms Tuesday when compared to competitors - MarketWatch

DexCom Inc. stock underperforms Tuesday when compared to competitors - MarketWatch

Here's Why You Should Retain DexCom Stock in Your Portfolio for Now - Zacks Investment Research

Here's Why You Should Retain DexCom Stock in Your Portfolio for Now - Yahoo Finance

DexCom (NASDAQ:DXCM): Affordable Growth at a Reasonable Valuation - ChartMill

Here's What to Expect From DexCom’s Next Earnings Report - inkl

Here's What to Expect From DexCom’s Next Earnings Report - Yahoo Finance

DXCMに類似

GEHC$76.570.20%

STE$227.122.16%

GKOS$237.602.01%

PEN$318.950.94%